ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals (ENTA) is a clinical-stage biotechnology company focused on designing and developing small-molecule antiviral therapies. Investors should know the company operates through a pipeline of preclinical and clinical candidates aimed at treating viral illnesses; revenues may be limited while programmes advance. Enanta often seeks partnerships or licensing deals with larger pharmaceutical companies to share development costs and commercialise products. The stock’s market capitalisation is around $306.94M, reflecting investor expectations about future pipeline milestones and licensing potential. Drug development is inherently high-risk and binary — clinical setbacks or regulatory delays can materially affect value, while successful trials or deals can be catalysts. This summary is educational, not personalised investment advice; investors should consider company filings, clinical data, financial position, and their own risk tolerance before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Enanta Pharmaceuticals' stock with a target price of $16, indicating strong potential for growth.
Financial Health
Enanta Pharmaceuticals is generating steady revenue and cash flow, but its overall financial health is moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ALTIMMUNE INC
Altimmune Inc is a clinical-stage biopharmaceutical company that develops immunotherapeutic products for the prevention and treatment of various diseases.
ADC THERAPEUTICS SA
Develops therapies for cancer treatments.
ACUMEN PHARMACEUTICALS INC
Acumen Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel therapies for the treatment of cancer and other life-threatening diseases.
Baskets Featuring ENTA
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and licensing deals can move the share price significantly, though outcomes are uncertain and timelines can be long.
Scientific Focus
Specialises in small-molecule antivirals, which can offer targeted, oral treatment options — but technical and regulatory hurdles remain.
Partnership Potential
Strategic collaborations with larger pharma can fund development and accelerate market access, though terms and timing vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
